 |
 |
 |
Management
Brad Thompson, Ph.D.
Chairman, President and Chief Executive Officer
Calgary, Alberta
Dr. Thompson has provided leadership to various organizations within the biotechnology sector for more than 20 years. He received his Ph.D. from the University of Western Ontario in the Department of Microbiology and Immunology, and is the current Chairman of the Board of BIOTECanada. |
| |
Doug Ball, C.A.
Chief Financial Officer
Calgary, Alberta
Mr. Ball is a senior executive with more than 25 years of experience in accounting, finance and developing and implementing effective business strategies. He is responsible for the financial affairs of Oncolytics, and provides financial and commercial input into the strategic direction of the company. Prior to joining Oncolytics, Mr. Ball held a variety of senior positions with organizations including SYNSORB Biotech, Canadian Airlines and Canadian Regional Airlines, Time Air and the Nu-West Group. |
| |
Matt Coffey, Ph.D.
Chief Operating Officer
Calgary, Alberta
A co-founder of Oncolytics Biotech Inc., Dr. Coffey’s current responsibilities include directing the research and development efforts, and integrating these efforts into an effective clinical trial program and intellectual property position for the Company. Prior to joining Oncolytics, Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in several respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. |
| |
Karl Mettinger, M.D., Ph.D
Chief Medical Officer
Berkeley, CA
Dr. Mettinger has been involved in clinical and regulatory affairs with various pharmaceutical companies since 1985. Prior to joining Oncolytics, he was Senior Vice President and Chief Medical Officer with SuperGen Inc. Prior to that, he was Executive Director, Clinical Research at IVAX/Baker Norton, which is the new drug subsidiary of IVAX Corporation. He began his career in the industry with KABI in Sweden. Dr. Mettinger holds an MD from the University of Lund in Sweden and a PhD (hematology/stroke) from the Karolinska Institute in Stockholm, Sweden. |
| |
George Gill, M.D.
Senior Vice President, Clinical and Regulatory Affairs
Washington, D.C.
George M. Gill, MD, has more than 30 years of senior-level experience in clinical research and regulatory affairs, and has supported the advancement of more than 20 products - including 11 cancer products - through the regulatory approval process in the United States, Canada and Europe. Prior to joining Oncolytics, Dr. Gill held top positions with several major pharmaceutical companies including ICI Pharmaceuticals (now AstraZeneca), The Bristol-Myers Company (now Bristol-Myers Squibb) and Hoffman-La Roche. Dr. Gill holds a B.Sc. (chemistry) from Dickinson College in Pennsylvania and an MD from the School of Medicine at the University of Pennsylvania. |
| |
Mary Ann Dillahunty, J.D., M.B.A.
Vice President, Intellectual Property
Half Moon Bay, CA
Ms. Dillahunty's career in the biopharmaceutical industry spans several decades and her experience ranges from patent portfolio development and prosecution to regulatory affairs consulting, business development and research science. Her responsibilities at Oncolytics include maximizing Oncolytics' patent potential for REOLYSIN® while offering senior level counsel to the Company on its strategic development. |
| |
Alan Warrander, Ph.D.
Senior Vice President, Global Licensing & Business Development
Manchester, U.K.
In his 32-year career, Dr. Warrander has held a number of positions within the biotechnology and pharmaceutical industries. He held a number of progressively senior positions in the pharmaceutical industry, most recently as Director, Global Licensing, AstraZeneca. Dr. Warrander subsequently served as Senior Vice President, Life Sciences at Wood Mackenzie, providing partnering support and advice to a range of clients on licensing, merger and acquisition and financing projects globally. He holds a PhD from the Department of Biochemistry at the University of Birmingham and a BSc in Chemistry and Biochemistry from the University of St. Andrews. Dr. Warrander was appointed to the Board of Oncolytics Biotech (Barbados) Inc. in December, 2008. |
| |
Directors
Brad Thompson, Ph.D.
Calgary, AB
Chairman, President and CEO, Oncolytics Biotech Inc. |
| |
Doug Ball, C.A.
Calgary, AB
Chief Financial Officer, Oncolytics Biotech Inc. |
| |
Ger J. van Amersfoort
The Netherlands
Former President and CEO of Novartis Canada from 1999 to 2001. Former President and CEO of SmithKline Beecham in Canada and the U.K. |
| |
William A. Cochrane, O.C., M.D.
Calgary, Alberta
President of W.A. Cochrane & Associates Inc. |
| |
Jim Dinning
Calgary, Alberta
Chairman, Western Financial Group. Former member of the legislative assembly of Alberta. |
| |
Ed Levy, Ph.D
Vancouver, B.C.
Adjunct professor at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. |
| |
J. Mark Lievonen, F.C.A.
Toronto, Ontario
President of Sanofi Pasteur Limited, responsible for the company's operations in Canada. |
| |
Robert B. Schultz
Toronto, Ontario
Former Chairman and CEO of Merrill Lynch Canada from August 1998 to May 1, 2000. Former Chairman, Rockwater Capital Corporation. |
| |
Fred A. Stewart, LL.B., Q.C.
Calgary, Alberta
President of Fred Stewart & Associates Inc. (government and corporate relations consulting company) since March 1996. |
| |
Scientific Advisory Board
Ramon Alemany, Ph.D.
Barcelona, Spain
Ramon Alemany, Ph.D. is a recognized expert on the development of antitumoral agents based on adenovirus. He is currently collaborating with Oncolytics to develop modified adenoviruses selective for Ras mediated cancers. |
| |
Richard Gorlick, M.D.
New York, NY
Dr. Gorlick is Chief, Section of Hematology/Oncology, Department of Pediatrics, the Children's Hospital at Montefiore. He is actively involved in the national pediatric cooperative group, the Children's Oncology Group. |
| |
Alan Tuchman, M.D.
New York, NY
Alan Tuchman, M.D., works in private practice and is a Clinical Professor of Neurology at New York Medical College. He is also the Executive Chairman of Neurophysics Corporation, a nuclear scanning technology company. |
| |
Frank Tufaro, Ph.D.
San Diego, CA
Frank Tufaro, Ph.D. has extensive start-up experience with biotechnology firms, and was one of the original founders of Neurovir Inc., a Vancouver-based biotech company which has now merged with MediGene AG to develop herpes simplex virus-based oncolytic vectors for cancer therapy. |
| |
Consultants
Alan Tuchman, M.D.
New York, New York |
| |
Daniel Von Hoff, M.D.
Tucson, AZ |
| |
|
|
|
|
